XNASLQDA
Market cap968mUSD
Dec 23, Last price
11.44USD
1D
3.06%
1Q
13.04%
IPO
4.09%
Name
Liquidia Corp
Chart & Performance
P/E
—
P/S
55.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
55.44%
Rev. gr., 5y
45.23%
Revenues
17m
+9.75%
Net income
-79m
L+104.62%
CFO
-42m
L+45.39%
Earnings
Mar 11, 2025
Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 17,488 9.75% | 15,935 23.98% | 12,853 1,637.81% | |||||
Cost of revenue | 90,872 | 54,705 | 46,650 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (73,384) | (38,770) | (33,797) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (2,650) | (4,797) | ||||||
Tax Rate | ||||||||
NOPAT | (73,384) | (36,120) | (29,000) | |||||
Net income | (78,502) 104.62% | (38,365) 28.82% | (29,782) -48.20% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 24,238 | 54,461 | 21,710 | |||||
BB yield | -3.10% | -14.03% | -8.97% | |||||
| Debt | ||||||||
Debt current | 2,278 | 1,081 | 1,086 | |||||
Long-term debt | 5,867 | 27,966 | 20,662 | |||||
Deferred revenue | (2,149) | (2,517) | ||||||
Other long-term liabilities | 50,125 | 6,594 | 6,144 | |||||
Net debt | (75,534) | (62,087) | (33,229) | |||||
| Cash flow | ||||||||
Cash from operating activities | (41,564) | (28,588) | (34,036) | |||||
CAPEX | (1,290) | (592) | (107) | |||||
Cash from investing activities | (11,288) | (587) | (107) | |||||
Cash from financing activities | 43,248 | 64,964 | 26,320 | |||||
FCF | (73,316) | (34,943) | (26,975) | |||||
| Balance | ||||||||
Cash | 83,679 | 93,283 | 57,494 | |||||
Long term investments | (2,149) | (2,517) | ||||||
Excess cash | 82,805 | 90,337 | 54,334 | |||||
Stockholders' equity | (429,029) | (350,532) | (309,529) | |||||
Invested Capital | 531,089 | 28,844 | 19,653 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 64,993 | 60,959 | 49,678 | |||||
Price | 12.03 88.85% | 6.37 30.80% | 4.87 65.08% | |||||
Market cap | 781,872 101.35% | 388,308 60.50% | 241,931 142.00% | |||||
EV | 706,338 | 326,221 | 208,702 | |||||
EBITDA | (71,206) | (35,123) | (28,185) | |||||
EV/EBITDA | ||||||||
Interest | 6,273 | 2,338 | 815 | |||||
Interest/NOPBT | ||||||||